{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 37,
  "pageCount": 58,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "data_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 19,
  "notes": "The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "bar_chart_horizontal",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/37",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-37",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Able to live monitor trial data is the primary rationale for adoption (79%), while lack of guidelines from NMPA/CDE (53%) is the leading barrier.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbe-a422b7ebfc34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.5,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Rationales on conducting / not conducting virtual trial / DCT",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac70c64f-f635-4797-9321-e963d83d85b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.35,
        "x": 0.038,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Pharmas' likelihood to conduct virtual trial / DCT in China in 2-3 years",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8b90ef3-34d0-4344-bbb4-a2bc608a3722",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.038,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Note: *Survey question: What is the likelihood of your company to conduct virtual trial / DCT in 2-3 years? **Survey question: What are the key reasons that your company is likely to conduct virtual trial / DCT in China? What are the key reason that your company is not likely to conduct virtual trial / DCT in China?",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f178162-7444-4576-b644-e0b609098db7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of respondents: 79%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbe-a9d81c5d8d71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.038,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: L.E.K. survey and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bde7e4da-a195-41d7-9dd9-dc2356ba7e8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.038,
        "y": 0.06
      },
      "kind": "title",
      "text": "Virtual trial / DCT: Respondents also show split attitude on likelihood to conduct virtual trial / DCT in China, with ability to live monitor trial data as key rationale for adoption",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f9bb83a-4b3f-4526-bd93-f3266647264d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Percent of respondents",
      "numberRaw": "79%",
      "numberKind": "percent",
      "actionTitle": "Virtual trial / DCT: Respondents also show split attitude on likelihood to conduct virtual trial / DCT in China, with ability to live monitor trial data as key rationale for adoption",
      "calloutText": "Able to live monitor trial data is the primary rationale for adoption (79%), while lack of guidelines from NMPA/CDE (53%) is the leading barrier.",
      "numberScale": null,
      "numberValue": 79,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}